July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Clinical outcomes of micropulse transscleral cyclophotocoagulation in post-keratoplasty patients
Author Affiliations & Notes
  • Jessica Minjy Kang
    UCSF, San Francisco, California, United States
  • Jennifer Rose-Nussbaumer
    UCSF, San Francisco, California, United States
  • Julie Marie Schallhorn
    UCSF, San Francisco, California, United States
  • David G. Hwang
    UCSF, San Francisco, California, United States
  • Ying Han
    UCSF, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Jessica Kang, None; Jennifer Rose-Nussbaumer, None; Julie Schallhorn, None; David Hwang, None; Ying Han, None
  • Footnotes
    Support  NIH-NEI EY002162 - Core Grant for Vision Research and the Research to Prevent Blindness Unrestricted Grant
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Minjy Kang, Jennifer Rose-Nussbaumer, Julie Marie Schallhorn, David G. Hwang, Ying Han; Clinical outcomes of micropulse transscleral cyclophotocoagulation in post-keratoplasty patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2826.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Uncontrolled glaucoma is an important risk factor for vision loss in post-keratoplasty patients. Management of such cases poses a challenge when patients are refractory to medical therapy. Previous studies have shown that both incisional glaucoma surgeries and traditional cyclodestructive laser procedures are associated with higher incidence of graft failure. Micropulse transscleral cyclophotocoagulation (MP-TSCPC) is a newer treatment for glaucoma that may offer IOP control with fewer complications in these patients. The purpose of this study was to evaluate the surgical outcomes and graft condition after MP-TSCPC in post-keratoplasty patients requiring better IOP control.

Methods : This was a retrospective observational study of patients with a history of penetrating keratoplasty (PKP) or Descemet’s Stripping Automated Endothelial Keratoplasty (DSAEK) who underwent MP-TSCPC from 09/2015 to 09/2017. IOP, number of glaucoma medications, visual acuity (VA), and central corneal thickness (CCT) were collected from the preoperative and postoperative month (POM) 1, 3, 6, and 12 visits. Postoperative complications, additional surgeries and graft failures were also recorded. Success of MP-TSCPC was defined as: 1) 5 mmHg ≤ IOP ≤ 21 mmHg OR reduction ≥20% from baseline at POM 12; 2) no use of oral carbonic anhydrase inhibitors, 3) no loss of light perception vision and 4) no reoperation for glaucoma within the 12-month follow up period.

Results : Thirty eyes from 28 patients (16 eyes post-PKP, 14 eyes post-DSAEK) were followed for average 10.5±2.79 months. The median time between the most recent corneal transplant and MP-TSCPC was 15.2 months. IOP was significantly decreased from pre-op at all follow up points (p<0.001). The number of glaucoma medications was significantly reduced only at POM 3 (p=0.002). There was no significant change in VA or CCT over the follow up period. At 12 months, 24 of the 30 eyes met the definition of success and only one underwent repeat PKP due to graft rejection.

Conclusions : MP-TSCPC achieved good IOP control success rates for post-keratoplasty patients with uncontrolled glaucoma. Patients maintained stable VA and had minimal rates of graft failure. Based on 12-month follow up, MP-TSCPC appears to be a safe and effective procedure following corneal transplant and may serve as an alternative to incisional surgery or traditional cyclodestructive laser procedures.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.